Last updated: 2026-09-05 22:52:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
ALX Oncology Holdings Inc. (ALXO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,01, with a market capitalization of $287,62M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,99 to $2,66. This page covers its latest market performance, valuation, price trends and company information.
$287,62M | |
$2,00 | |
$117,45 | |
$0,40 | |
$2,03 | |
245,96K | |
-- | |
-- | |
$2,66 | |
$0,99 | |
-- | |
-- |
ALX Oncology Holdings Inc. (ALXO) last closed at $2,03 as of 2026-09-04 23:31:00, unchanged from the previous close of $2,03.
During the latest regular trading session, ALXO traded between $0,40 and $117,45, with a volume of 245,96K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, ALX Oncology Holdings Inc. (ALXO) moved from $2,07 to $2,01, representing a decline of 3,14% ($0,06).
The stock traded between $1,97 and $2,03 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 688,38 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 60,8%
ALXO is currently trading at $2,01, placing it 60,8% of the way from its 52-week low of $0,99 to its 52-week high of $2,66. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 48 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ALX Oncology Holdings Inc. (ALXO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.